

QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C FOR THE PERIOD ENDED 31 MARCH 2023

ASX:RLG 28 April 2023

Q3 FY2023 APPENDIX 4C & KEY FINANCIAL DATA



Q3 FY2023

\$ 2.26m

CASH RECEIPTS Q3 FY2023

\$(1.87m)

PRODUCT & OPERATING COSTS PAYMENTS 03 FY202

\$(915k) NET CASH USED IN Q1-Q3 <u>FY2023</u>

\$ 9.55m

CASH RECEIPTS Q1-Q3 FY202<mark>3</mark>

\$(7.04m)

PRODUCT & OPERATING COST PAYMENTS Q1-Q3 FY2023

\$(1.45m)

NET CASH USED IN OPERATING ACTIVITIES Q1-Q3 FY2023 VS

-8.9%

Decline

+23.4%

Improvement

+56.5%

Improvement

Q1-Q3 <u>FY2022</u>

\$10.48m

CASH RECEIPTS Q1-Q3 FY2022

\$(9.19m)

PRODUCT & OPERATING COSTS PAYMENTS Q1-Q3 FY2022

\$(3.33m

NET CASH USED IN OPERATING ACTIVITIES Q1-Q3 FY2022 Q3 FY2023

\$3.0m

Q3 FY2023

\$ 2.3m

OTAL WORKING CAPITAL AND AVAILABLE FUNDING

RLG'S BUSINESS FOCUS TO TARGET IMPROVED FUTURE PROFITABILITY

RLG UNLOCK A WORLD OF POTENTIAL

- Responded to changing consumer behaviour based on COVID conditions, consumer health focus & supply chain interruptions with tactical product & brand selection
- Increased focus on lucrative high-growth health, wellbeing and food products
- Pursuit of higher margin sales (Gross Profit on product sales increasing)
- Expanded customer reach through key partnerships
- Investment and launch of company-owned Food Health Brand VORA in Australia and China
- Strengthened RLG's capacity to benefit from China's re-opening and increasing health awareness



Q3 FY2023 OPERATIONAL HIGHLIGHTS

RLG UNLOCK A WORLD OF POTENTIAL

- RLG Health, Food & Wellbeing products range achieving good sales traction in post-COVID China with brands including:
 - > AFT Pharmaceuticals
 - > New Zealand Honey Co
 - > Remedy Drinks
 - > VORA
- VORA is RLG's own new Health & Wellness Brand "Good for You, Good for the Planet. Good Business" launched in Australia and China
- RLG appointed to market and sell FIJI KAVA online in China and Australia
- RLG secures stocking and distribution in Alibaba's Freshippo Stores and online platform in China for its exclusive Remedy Drinks range
- Removal of China's COVID restrictions driving online and in-market spending by consumers



Q3 FY2023 - RLG SECURES DISTRIBUTION IN ALIBABA'S 300



FRESHIPPO STORES

- RLG launched Remedy Drinks into Alibaba's 300 high-tech Freshippo Stores
- First orders received and first product delivered to stock stores and service online orders
- Shoppers can buy in person or shop online from Alibaba's retail omnichannel

During the Quarter, RLG launched Remedy Drinks in Alibaba's 300 bricks-and-mortar Freshippo stores located in 27 cities across China.

Additionally the products are now available to be purchased online through the Alibaba operated Freshippo official app.

With this addition, Remedy Drinks range of products is now sold and available in over 500 physical points of sale around China.

First order was received in March to stock Freshippo stores.





RLG APPOINTED TO MARKET & SELL FIJI KAVA IN CHINA &

RLG UNLOCK A WORLD OF POTENTIAL

AUSTRALIA

Following the Quarter end, RLG was appointed by Fiji Kava (ASX:FIJ)/The Calmer Co (ASX:CCO), a global beverage and natural medicine company, as its distributor for China and Australia.



RLG is to manage and operate Fiji Kava's Australian-based online sales operations via www.fijikava.com and also to market and sell the Fiji Kava range including relaxant and sleep aid capsules, drinking kava, dietary shots and new ready to drink 'RTD' products in China.

RLG is to co-market the Fiji Kava powdered drinking kava range alongside its VORA (<u>www.vora.com.au</u>) protein range in the lucrative online sports nutrition channel in Australia and in China, where more than 80% of sales take place by eCommerce¹

RLG to generate revenue through multiple channels including service fees, digital marketing fees, margins on all product sales and Performance Rights for sales achievements (As announced to ASX - 12 April 2023)





AUSTRALIA & CHINA

OF POTENTIAL

- VORA Healthy Food Brand developed to provide RLG increased margins on products sold under own brand with ability to respond and service identified consumer demand rapidly
- RLG to leverage the customer databases built in China over time to sell VORA products to a qualified customer base
- VORA launched in Australia followed by China and it is planned to expand into a broader food range to service high-demand and high growth markets in China and South Fast Asia
- VORA sales commenced and grew in Q3 FY2023
- RIG to co-market and sell its VORA (<u>www.vora.com.au</u>) protein range alongside the Fiji Kava range in the lucrative online sports nutrition channel in Australia and in China.
- South Fast Asia sales and distribution partnerships being sought







only one decision



















Q3 FY2023

Corporate, Financial Performance & Other Cash Items

- Payments for staff costs, including directors, in the quarter totalled \$866k and included payments for services provided for FY2022.
- Administration and corporate costs in the quarter wer \$217k down from \$282k in the prior quarter.
- Fees paid to Non-Executive Directors were \$30k and fees paid to Executive Directors during the Quarter totalled \$245k and included bonus payments of \$131k related to achievement of milestone targets and reported in FY2022.











RLG MULTI-CHANNEL REVENUE MODEL

REVENUE FROM RECURRING SERVICES FEES + PRODUCT SALES













RLG CONNECTS GLOBAL BRANDS WITH CUSTOMERS



- An established, leading e-commerce platform provider
- Selling food, health and well being products
- Global Client Base 7 Countries
- Own Brand VORA "Good for you" Food Products launched
- Market Focus Australia, South East Asia & Emerging Markets
- Targeting growing margin on Product Sales



RLG China Channel Network

























Online & Offline B2B











High End Retail Grocery











High End Retail Trade









Specialty Retail (Gyms/Clubs/Hotels)











Government Organizations/Events/Seminars/Training













ASX:RLG BUSINESS OVERVIEW



SELLING FOOD, HEALTH AND WELLBEING PRODUCTS ONLINE AND VIA CHANNELS

- RLG matches consumer demand with brands via multiple channels
- RLG drives online and in-market sales of international brands
- RLG's own Healthy Food Brand VORA launched
- Strong China focus the largest e-commerce market globally, generating almost 50% of the world's transactions, valued at \$USD2.3 trillion and providing access to 940 million online shoppers*
- The size of the addressable market and RLG's established platform for accessing this market provides a solid foundation to drive toward future growth and profitability
- Removal of COVID restrictions in China in December 2022 is expected to drive strong consumer spending in 2023*











[•] www.trade.gov/country-commercial-guides/china-ecommerce, www.statista.com/statistics/663464/alibaba-cumulative-active-mobile-users-taobao-tmall/

https://www2.deloitte.com/cn/en/pages/about-deloitte/articles/deloitte-research-issues-79.html

RLG BUSINESS SUMMARY



Compelling in- demand service:	E-commerce & sales platforms selling food, health and wellbeing products.
Proven platform ready for scale:	Strong international product range from NZ, UK, Europe, USA, South America, Australia.
Infrastructure investment creates turnkey solution:	China team, Australian team, logistics, warehousing, translation, marketing, distribution and e-commerce support for rapid market entry.
Company Owned Health Brand:	VORA – "Good for you" health food range, selling into high demand, high growth markets, delivering margin benefits & ability to rapidly respond to demand.
Revenue Growth:	Mix of stable recurring revenues and product sales with annual revenue of \$700k (FY19) to \$16.9m (FY22).







ASX:RLG

Twitter \$RLG_Investors

LinkedIn RooLife Group

Website www.roolifegroup.com.au

Issued by: RooLife Group Ltd Authorised by: The Board of RooLife Group Ltd

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

RooLife Group Limited

ABN

Quarter ended ("current quarter")

14 613 410 398 31 March 2023

Con	solidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000	
1.	Cash flows from operating activities			
1.1	Receipts from customers	2,260	9,546	
1.2	Payments for			
	(a) research and development	-	-	
	(b) product manufacturing and operating costs	(1,865)	(7,040)	
	(c) advertising and marketing	(186)	(692)	
	(d) leased assets	-	-	
	(e) staff costs	(866)	(2,370)	
	(f) administration and corporate costs	(217)	(795)	
1.3	Dividends received (see note 3)	-	-	
1.4	Interest received	-	8	
1.5	Interest and other costs of finance paid	(8)	(18)	
1.6	Income taxes paid	-	-	
1.7	Government grants and tax incentives	-	79	
1.8	Other (provide details if material)	(33)	(164)	
1.9	Net cash from / (used in) operating activities	(915)	(1,446)	

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(1)	(10)
	(d) investments	-	-
	(e) intellectual property	(21)	(58)
	(f) other non-current assets	-	-

ASX Listing Rules Appendix 4C (17/07/20)

Page 1

Con	solidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	(8)	21
2.6	Net cash from / (used in) investing activities	(30)	(47)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	150	600
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	150	600

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,300	2,416
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(915)	(1,446)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(30)	(47)

Con	solidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	150	600
4.5	Effect of movement in exchange rates on cash held	9	(9)
4.6	Cash and cash equivalents at end of period	1,514	1,514

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,514	2,300
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,514	2,300

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	275 ¹
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
	if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must includ nation for, such payments.	le a description of, and an

 $^{^{1}\,}$ Payments totalling \$275,000 were made to directors for fees and superannuation on fees.

7.	Financing facilities Note: the term "facility' includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	1,000	600
7.2	Credit standby arrangements	50	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities 1,050		600
7.5	Unused financing facilities available at qu	450	

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Working Capital Loan Agreement for a line of credit of \$1,000,000, with Saxby Capital Investments Pty Ltd, to be drawn on a case-by-case basis for each sale of product into China. Interest is calculated at 10% per annum on loan amount drawn down, payable in arrears. Repayment of the drawn down amount of \$600,000 is due on 1 April 2024. The finance facility is secured by a fixed and floating charge over receivables and inventory to the equivalent value of amount outstanding of the Loan.

Business Overdraft Facility of \$49,999 with Australia and New Zealand Banking Group Limited (ANZ) at an interest rate of 10.45%. The facility is unsecured and has no fixed maturity date.

8.	Estimated cash available for future operating activities	\$A'000		
8.1	Net cash from / (used in) operating activities (item 1.9)	(915)		
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,514		
8.3	Unused finance facilities available at quarter end (item 7.5)	450		
8.4	Total available funding (item 8.2 + item 8.3)	1,964		
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.15		
	Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.			

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer	: N/A				

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A			

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 April 2023

Authorised by: The Board of RooLife Group Ltd

Notes

- 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.